Menu
Exonate
Exonate develops and licenses Vascular Endothelial Growth Factors (VEGF) control agents that may be used as therapeutics in areas such as pain control, macular degeneration and cancer.
Drug discovery – wet AMD and cancer
School of Medicine
Profile
Exonate’s research in this area has identified therapeutic candidates for wet Age Related Macular Degeneration that can be administered as a simple eye drop, thereby over-coming the unpleasant need for monthly injections in the eye.
Competing injectable anti-VEGFdirected therapy currently constitutes the gold-standard treatment for wet Age Related Macular Degeneration (wAMD) and other neovascular diseases of the eye.
News and press releases
@ExonateUK on Twitter
Really excited that our CEO,
@Beech_Catherine
representing us at #biotrinity conference 28th April-1st May, joining a fantastic line-up of speakers and is featured in a 30-minute case study showcasing her career path, business strategy and the importance of a strong team
Wonderful news Exonate have been shortlisted into the final round in the Most Impactful UK Deal category of the 2020 OBN Awards on the 26th November 2020
Patients with diabetic macular oedema receiving anti-VEGF injections have worse outcomes than in clinical trials, likely due to undertreatment. Reducing the need for injections with new treatments could help improve patient outcomes @ExonateUK https://twitter.com/ClinExpOphthal/status/1296760702170853376
10 yr outcomes of anti‐VEGF for neovascular #maculardegeneration. 10% gained, 64% lost ≥10 letters, 23% remained stable; 93% geographic atrophy, 71% subretinal fibrosis. Vision worse in pre‐treated eyes than naïve. Wolff et al.
https://doi.org/10.1111/ceo.13742
Exonate’s Lab has moved, and we’re officially back up and running! The LCMS, culture hoods and incubators are now fully operational in the new laboratory at Medicity; a major step in pushing forward the in-house experimental programme
Excellent article from Exonate’s Senior Scientist Cristina Gutierrez-Caballero in The Biochemist Vol.42 No.2
Excellent article from Exonate’s Senior Scientist Cristina Guttierrez-Cabellero in The Biochemist Vol.42 No.2
@RANZCO clinical #COVID19 guidance is to continue anti-VEGF injections and maximise treat and extend for high risk #DME #wetAMD patients. Eye drops that reduce hospital visits and maintain treatment frequency are now key to safely prevent vision loss #newnormal